Log in to save to my catalogue

Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall Survival? A Comparative Effectivene...

Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall Survival? A Comparative Effectivene...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_1520401677

Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall Survival? A Comparative Effectiveness Study in a Population-Based Sample

About this item

Full title

Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall Survival? A Comparative Effectiveness Study in a Population-Based Sample

Publisher

United States: Public Library of Science

Journal title

PloS one, 2014-05, Vol.9 (5), p.e94977-e94977

Language

English

Formats

Publication information

Publisher

United States: Public Library of Science

More information

Scope and Contents

Contents

Epidermal growth factor receptor (EGFR) inhibitors are approved for treating metastatic colorectal cancer (CRC); KRAS mutation testing is recommended prior to treatment. We conducted a non-inferiority analysis to examine whether KRAS testing has impacted survival in CRC patients.
We included 1186 metastatic CRC cases from seven health plans. A c...

Alternative Titles

Full title

Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall Survival? A Comparative Effectiveness Study in a Population-Based Sample

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_plos_journals_1520401677

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_1520401677

Other Identifiers

ISSN

1932-6203

E-ISSN

1932-6203

DOI

10.1371/journal.pone.0094977

How to access this item